Find Frunexian manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Ep-7041, 1803270-60-1, Bke5cvp3fs, (2s,3r)-3-((2-aminopyridin-4-yl)methyl)-1-(((1r)-1-cyclohexylethyl)carbamoyl)-4-oxoazetidine-2-carboxylic acid, (2s,3r)-3-[(2-aminopyridin-4-yl)methyl]-1-[[(1r)-1-cyclohexylethyl]carbamoyl]-4-oxoazetidine-2-carboxylic acid, (2s,3r)-3-[(2-aminopyridin-4-yl)methyl]-1-{[(1r)-1-cyclohexylethyl]carbamoyl}-4-oxoazetidine-2-carboxylic acid
Molecular Formula
C19H26N4O4
Molecular Weight
374.4  g/mol
InChI Key
NYPSZHLKEMYZKK-XFJVYGCCSA-N
FDA UNII
BKE5CVP3FS

Frunexian
FRUNEXIAN is a small molecule drug with a maximum clinical trial phase of II (across all indications) and has 1 investigational indication.
1 2D Structure

Frunexian

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S,3R)-3-[(2-amino-4-pyridinyl)methyl]-1-[[(1R)-1-cyclohexylethyl]carbamoyl]-4-oxoazetidine-2-carboxylic acid
2.1.2 InChI
InChI=1S/C19H26N4O4/c1-11(13-5-3-2-4-6-13)22-19(27)23-16(18(25)26)14(17(23)24)9-12-7-8-21-15(20)10-12/h7-8,10-11,13-14,16H,2-6,9H2,1H3,(H2,20,21)(H,22,27)(H,25,26)/t11-,14-,16+/m1/s1
2.1.3 InChI Key
NYPSZHLKEMYZKK-XFJVYGCCSA-N
2.2 Other Identifiers
2.2.1 UNII
BKE5CVP3FS
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Ep-7041

2.3.2 Depositor-Supplied Synonyms

1. Ep-7041

2. 1803270-60-1

3. Bke5cvp3fs

4. (2s,3r)-3-((2-aminopyridin-4-yl)methyl)-1-(((1r)-1-cyclohexylethyl)carbamoyl)-4-oxoazetidine-2-carboxylic Acid

5. (2s,3r)-3-[(2-aminopyridin-4-yl)methyl]-1-[[(1r)-1-cyclohexylethyl]carbamoyl]-4-oxoazetidine-2-carboxylic Acid

6. (2s,3r)-3-[(2-aminopyridin-4-yl)methyl]-1-{[(1r)-1-cyclohexylethyl]carbamoyl}-4-oxoazetidine-2-carboxylic Acid

7. Refchem:137078

8. Frunexian (usan)

9. Frunexian [usan]

10. Frunexian [inn]

11. Orb2277627

12. Chembl5314583

13. Schembl16997955

14. Gtpl11990

15. Ep 7041 [who-dd]

16. Bdbm50621716

17. Ep7041

18. Da-73563

19. Hy-156613

20. Cs-0886205

21. D12563

22. 2-azetidinecarboxylic Acid, 3-[(2-amino-4-pyridinyl)methyl]-1-[[[(1r)-1-cyclohexylethyl]amino]carbonyl]-4-oxo-, (2s,3r)-

2.4 Create Date
2016-02-23
3 Chemical and Physical Properties
Molecular Weight 374.4 g/mol
Molecular Formula C19H26N4O4
XLogP32.6
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count6
Rotatable Bond Count5
Exact Mass Da
Monoisotopic Mass Da
Topological Polar Surface Area126
Heavy Atom Count27
Formal Charge0
Complexity578
Isotope Atom Count0
Defined Atom Stereocenter Count3
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty